Witnessing the stock’s movement on the chart, on Thursday, Atara Biotherapeutics Inc (NASDAQ: ATRA) had a quiet start as it plunged -3.25% to $0.69, before settling in for the price of $0.71 at the close. Taking a more long-term approach, ATRA posted a 52-week range of $0.20-$3.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 25.21%. Meanwhile, its Annual Earning per share during the time was 13.12%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 79.08%. This publicly-traded company’s shares outstanding now amounts to $119.36 million, simultaneously with a float of $110.12 million. The organization now has a market capitalization sitting at $82.56 million. At the time of writing, stock’s 50-day Moving Average stood at $0.7340, while the 200-day Moving Average is $1.1140.
Atara Biotherapeutics Inc (ATRA) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Atara Biotherapeutics Inc’s current insider ownership accounts for 7.74%, in contrast to 60.76% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’24, this organization’s President and CEO sold 24,844 shares at the rate of 0.72, making the entire transaction reach 17,888 in total value, affecting insider ownership by 1,910,652. Preceding that transaction, on Mar 04 ’24, Company’s EVP, Chief Sci. & Tech Officer sold 10,746 for 0.72, making the whole transaction’s value amount to 7,737. This particular insider is now the holder of 941,397 in total.
Atara Biotherapeutics Inc (ATRA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.69 per share during the current fiscal year.
Atara Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 79.08% and is forecasted to reach -0.40 in the upcoming year.
Atara Biotherapeutics Inc (NASDAQ: ATRA) Trading Performance Indicators
Let’s observe the current performance indicators for Atara Biotherapeutics Inc (ATRA). It’s Quick Ratio in the last reported quarter now stands at 0.65. The Stock has managed to achieve an average true range (ATR) of 0.07. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.63.
In the same vein, ATRA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.61, a figure that is expected to reach -0.26 in the next quarter, and analysts are predicting that it will be -0.40 at the market close of one year from today.
Technical Analysis of Atara Biotherapeutics Inc (ATRA)
Going through the that latest performance of [Atara Biotherapeutics Inc, ATRA]. Its last 5-days volume of 1.12 million was inferior to the volume of 2.79 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 26.34% While, its Average True Range was 0.0607.
Raw Stochastic average of Atara Biotherapeutics Inc (ATRA) in the period of the previous 100 days is set at 22.60%, which indicates a major fall in contrast to 22.85% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.71% that was lower than 133.02% volatility it exhibited in the past 100-days period.
